B. Riley Cuts Harrow (NASDAQ:HROW) Price Target to $65.00

Harrow (NASDAQ:HROW) had its price objective reduced by B. Riley from $69.00 to $65.00 in a research note published on Tuesday morning,Benzinga reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for Harrow’s Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at $0.17 EPS, Q3 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.38 EPS, FY2025 earnings at $0.78 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $4.79 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $57.00 price objective on shares of Harrow in a research report on Monday.

Harrow Trading Down 7.6 %

Shares of NASDAQ:HROW opened at $24.06 on Tuesday. The company has a market cap of $857.84 million, a PE ratio of -25.60 and a beta of 0.46. The company’s 50 day moving average is $28.17 and its two-hundred day moving average is $37.54. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW) last issued its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. The business had revenue of $66.83 million during the quarter, compared to analysts’ expectations of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Equities analysts predict that Harrow will post -0.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harrow

Hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after buying an additional 194,480 shares in the last quarter. Barclays PLC grew its holdings in Harrow by 301.9% during the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after acquiring an additional 39,506 shares during the period. Charles Schwab Investment Management Inc. raised its position in Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock worth $11,313,000 after acquiring an additional 166,602 shares in the last quarter. State Street Corp raised its position in Harrow by 2.2% in the third quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after acquiring an additional 15,554 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Harrow in the third quarter valued at $1,469,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.